PUBLIC COMPANY
save$FOLDAMICUS THERAPEUTICS, INC.
$FOLD14.490.00%Princeton, NJ, USupdated 2mo ago
Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, Pennsylvania. The company went public in 2007 under the Nasdaq trading symbol FOLD. This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates.
community read0 votes
pipeline
4
marketed
3
phase 3
1
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
1Phase 33Marketed
Upcoming
no upcoming catalysts on record
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —A Study of Patients With Fabry Disease (US Specific)
- phase3A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
- phase3A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
- —A Global Prospective Observational Registry of Patients With Pompe Disease
- phase3A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With Late-Onset Pompe Disease (LOPD)
- phase3Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
- —A Study to Describe the Experience of Both Patients and Their Clinicians in the Treatment of Fabry Disease With Enzyme Replacement Therapy.
- phase3A Study to Evaluate the Safety, Efficacy, PK, PD and Immunogenicity of Cipaglucosidase Alfa/Miglustat in IOPD Subjects Aged 0 to <18
🐶 Hiring Signal
News
- Foghorn cuts 40% of workforceFollow along as BioSpace tracks job cuts and restructuring initiatives.biospace · 3d ago
- Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027Jefferies analysts made the prediction after Sarepta Therapeutics, which has endured nothing short of a saga with the Duchenne muscular dystrophy gene therapy Elevidys, presented data this week sho…biospace · 3d ago
- HHS kicks off new programs to speed clinical trials as Chinese competition loomsThe department is offering funding to teams with innovative proposals as it considers ending the traditional phased clinical trial system.biopharma_dive · 4d ago
- Trump administration appeals ruling blocking limits on international student visasDHS has appealed a court ruling blocking it from restricting how long international students and postdoctoral researchers can remain in the U.S.stat · 4d ago
- Opinion: I studied GLP-1 use in children. The results are reassuring“Intervening in childhood could save children from decades of irreversible damage,” a transplant surgeon writes of GLP-1 weight loss drugs.stat · 4d ago
- Travere CEO Eric Dube on deciding to leave; Roche tees up a board seat for ex-Takeda chiefOn Dec. 1, Travere Therapeutics will have a new CEO for the first time in almost eight years, as Eric Dube hands the baton to former Amicus Therapeutics CEO Bradley Campbell. The commercial-stage r…endpoints · 10d ago
- At least five candidates vie to become the next WHO leader, as questions over U.S. role loomAt least five candidates are in the running to become the next director-general of the WHO, a job that will come with extraordinary challenges.stat · 10d ago
- FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’FDA inspectors found evidence that the compounding pharmacy was making versions of Eli Lilly’s tirzepatide and Novo’s semaglutide “regularly or in inordinate amounts” at a site with “insanitary con…biospace · 10d ago
- Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitzNovo plans to hit $23B in revenue by 2035, has further reduced its workforce by 4,000 and is boosting manufacturing capacity for its Wegovy pill, but investors are unconvinced it will be enough to…biospace · 12d ago
- Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.biospace · 13d ago
Data sources
last refreshed 31m ago
Found something off?
comments(0)
5-min edit window · permanent after that